 |
264 Diseases |  |
12 Trials |
|
12 Trials |  |
579 News |  |
| «12345678» |
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma (clinicaltrials.gov) - May 13, 2014
P1/2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial primary completion date, Metastases: Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer (clinicaltrials.gov) - May 8, 2014
P1, N=56, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2013 --> Dec 2014
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change, Metastases: Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer (clinicaltrials.gov) - May 8, 2014
P1, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2013 --> Dec 2014 N=56 --> 74
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov) - May 8, 2014
P2, N=123, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=56 --> 74 N=93 --> 123
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Combination therapy: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P1, N=100, Completed, Sponsor: National Cancer Institute (NCI)
N=93 --> 123 Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Combination therapy, Metastases: Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=70, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | pirfenidone / Generic mfg.
Trial completion: Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas (clinicaltrials.gov) - Feb 22, 2014
P2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma (clinicaltrials.gov) - Feb 22, 2014
P2, N=90, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Tipifarnib in Treating Patients With Metastatic Malignant Melanoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Feb 22, 2014
P2, N=54, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Combination therapy, Metastases: Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Combination therapy, Metastases: Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=55, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Suspended --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=62, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) (clinicaltrials.gov) - Feb 22, 2014
P2, N=44, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=125, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=154, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=12, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: R115777 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: City of Hope Medical Center
No longer recruiting --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=100, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas (clinicaltrials.gov) - Feb 19, 2014
P2, N=62, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Combination therapy, Metastases: R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Tipifarnib in Treating Patients With Advanced Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Suspended --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: North American Brain Tumor Consortium
Suspended --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (clinicaltrials.gov) - Feb 19, 2014
P2, N=7, Completed, Sponsor: Fox Chase Cancer Center
No longer recruiting --> Completed No longer recruiting --> Completed
- | Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Feb 6, 2014
P1/2, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed N=86 --> 60
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change, Metastases: Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 5, 2014
P1, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=86 --> 60 N=42 --> 29
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: R115777 in Treating Patients With Advanced Bladder Cancer (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=42 --> 29 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial termination: Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Oct 6, 2013
P1/2, N=64, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Zarnestra (tipifarnib) / Kura Oncology
Trial initiation date: Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma (clinicaltrials.gov) - Oct 6, 2013
P2, N=90, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Jul 2003 --> Nov 2003
- | Zarnestra (tipifarnib) / Kura Oncology, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion: Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Aug 22, 2013
P2/3, N=2000, Completed, Sponsor: The University of New South Wales
Initiation date: Jul 2003 --> Nov 2003 Recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 9, 2013
P2, N=21, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed N=35 --> 21
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment closed, Combination therapy, Metastases: Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jun 30, 2013
P1/2, N=45, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=35 --> 21 Suspended --> Active, not recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 30, 2013
P1, N=65, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Suspended --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment closed: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 12, 2013
P2, N=21, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Suspended --> Completed Recruiting --> Active, not recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia (clinicaltrials.gov) - Jun 2, 2013
P2, N=35, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Trial termination: Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia (clinicaltrials.gov) - May 5, 2013
P2, N=25, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia (clinicaltrials.gov) - May 5, 2013
P2, N=25, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated N=56 --> 25
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment closed: Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 30, 2013
P2, N=35, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=56 --> 25 Recruiting --> Active, not recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Apr 7, 2013
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=52 --> 19
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Apr 7, 2013
P1/2, N=183, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=52 --> 19 Completed --> Active, not recruiting
- Zarnestra (tipifarnib) / Kura Oncology
Trial initiation date: Tipifarnib in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jan 15, 2013
P1, N=65, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Initiation date: Sep 2000 --> Jun 2002
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Trial completion, Surgery, Metastases: Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 10, 2013
P2, N=120, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Sep 2000 --> Jun 2002 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change: Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 3, 2013
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=45 --> 30
- Zarnestra (tipifarnib) / Kura Oncology
Enrollment change, Metastases: Tipifarnib in Treating Patients With Metastatic Malignant Melanoma (clinicaltrials.gov) - Dec 18, 2012
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
N=45 --> 30 N=14 --> 40
- Zarnestra (tipifarnib) / Kura Oncology
Trial initiation date, Combination therapy, Metastases: Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 10, 2012
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
N=14 --> 40 Initiation date: Nov 2002 --> Oct 2003